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Abstract
Objectives: To compare the effect of nebulized racemic epinephrine to nebulized racemic albuterol on
successful discharge from the emergency department (ED).
Methods: Children up to their 18th month of life presenting to two teaching hospital EDs with a clinical
diagnosis of bronchiolitis who were ill enough to warrant treatment but did not need immediate intuba-
tion were eligible for this double-blind randomized controlled trial (RCT). Patients received either three
doses of racemic albuterol or one dose of racemic epinephrine plus two saline nebulizers. Disposition
was decided 2 hours after the ﬁrst nebulizer. Successful discharge was deﬁned as not requiring addi-
tional bronchodilators in the ED after study drug administration and not subsequently admitted within
72 hours. Adjusted relative risks (aRR) were estimated using the modiﬁed Poisson regression with suc-
cessful discharge as the dependent variable and study drug and severity of illness as exposures. Second-
ary analysis was performed for patients aged less than 12 months and ﬁrst presentation.
Results: The authors analyzed 703 patients; 352 patients were given albuterol and 351 epinephrine. A
total of 173 in the albuterol group and 160 in the epinephrine group were successfully discharged (crude
RR = 1.08, 95% conﬁdence interval [CI] = 0.92 to 1.26). When adjusted for severity of illness, patients
who received albuterol were signiﬁcantly more likely than patients receiving epinephrine to be success-
fully discharged (aRR = 1.18, 95% CI = 1.02 to 1.36). This was also true among those with ﬁrst presenta-
tion and in those less than 12 months of age.
Conclusions: In children up to the 18th month of life, ED treatment of bronchiolitis with nebulized race-
mic albuterol led to more successful discharges than nebulized epinephrine.
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B
ronchiolitis is a common childhood disease. It is
a leading cause of hospitalization worldwide and
accounts for substantial morbidity and a mortal-
ity of less than 1%.
1,2 Between 1980 and 1996, annual
infant hospitalization rates for bronchiolitis doubled to
34 per 1,000, while rates for other lower respiratory tract
diseases remained stable.
3 In 2002, bronchiolitis resulted
in 149,000 hospital admissions and annual costs of
$543 million in the United States.
4
Bronchodilator therapy in bronchiolitis is controver-
sial. Although commonly used,
5 its efﬁcacy is not univer-
sally accepted. Small studies
6–9 and systematic reviews
have shown small, short-term improvement in clinical
scores in outpatient use of albuterol.
10 There is, how-
ever, no convincing evidence that albuterol decreases
the admission rate in outpatients.
10 Some,
11–13 but not
all,
14–16 small studies suggest that epinephrine may
decrease admissions in outpatients. A Cochrane review
ª 2008 by the Society for Academic Emergency Medicine ISSN 1069-6563
doi: 10.1111/j.1553-2712.2008.00064.x PII ISSN 1069-6563583 305
From the Department of Emergency Medicine (PW, SF, DR), the Pharmacy Department (JC), Kern Medical Center, Bakersﬁeld,
CA; the David Geffen School of Medicine at UCLA (PW), Los Angeles, CA; the Department of Emergency Medicine, Advocate
Christ Medical Center (KKM), Oak Lawn, IL; the Department of Emergency Medicine, Central Maine Medical Center (KKM),
Lewiston, ME; Departamento de Ecología Humana, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico
Nacional (I.P.N.), Unidad Mérida, Mérida (SJR), Yucatán; Centro de Estudios de Salud Poblacional, Instituto Nacional de Salud
Pública, Cuernavaca (SJR), Morelos, México.
Received August 28, 2007; revisions received November 13 and November 30, 2007; accepted December 1, 2007.
Presented at the Society for Academic Emergency Medicine Plenary Session, Chicago, IL, May 2007.
All authors declare that they have no competing interests nor have they received any pharmaceutical company funding or hono-
raria. This study did not receive extramural funding.
NCT # 00114478.
Address for correspondence and reprints: Paul Walsh, MB, BCh, BAO; e-mail: yousentwhohome@gmail.com.of these studies was inconclusive, however, because of
the small numbers overall.
17 For the largest study
included in that review (comparing racemic albuterol
and epinephrine in outpatients), the power to detect a
change in admissions of 15% from 50% was 23%. Even
if all the cases in that review had been combined in a sin-
gle study, the power would have been 58%.
The inconclusive results obtained to date suggest that
if there is a difference in disposition between racemic
albuterol- and epinephrine-treated patients, it is mod-
est. It seems likely that the most important factor pre-
dicting the need for admission will be the severity of
the bronchiolitis. Without a severity assessment tool
validated to predict the need for admission in bronchio-
litis, unmeasured but uneven distribution of factors that
inﬂuence disposition can confound a modest, yet
important treatment effect.
The most commonly used tool for severity assess-
ment is the respiratory distress assessment instrument
(RDAI). It was originally described in an inﬂuential
early study evaluating the effect of subcutaneous epi-
nephrine in bronchiolitis.
12 The RDAI produces precise
scores and is reliable among different users. Although
subsequently validated in asthma, it has not been vali-
dated for predicting admission in bronchiolitis.
18
Despite being widely used, because the RDAI limits its
assessment to the respiratory system,
12 applying it to
infants with bronchiolitis is problematic. By failing to
incorporate age it assigns a 3-week-old infant with
wheezing a low score, but assigns a high score to an
11-month ‘‘happy wheezer’’ with audible wheeze and
chest wall retractions.
12 It also does not address other
clinical ﬁndings such as dehydration, which inﬂuence
disposition in infants and toddlers.
Prior to undertaking this randomized controlled trial
(RCT), we derived a severity-of-illness tool in bronchio-
litis patients deﬁning ‘‘admission not needed,’’ ‘‘length
of hospital stay up to and including the median,’’ and
‘‘length of hospital stay greater than the median,’’ as
ordinal outcome measures. During the derivation of
this ordinal regression model, we found that age, dehy-
dration, retraction severity, and tachycardia predicted
the outcome.
19 We subsequently validated this model at
a different children’s hospital and measured its inter-
rater reliability at a third site.
20 This ordinal regression
model reﬂects the systemic consequences of bronchioli-
tis in addition to the respiratory component and mea-
sures a meaningful outcome. It is presented in Figure 1.
The primary objective of this study was to compare
the effect of nebulized racemic albuterol to nebulized
racemic epinephrine on discharge rates among children
presenting to the emergency department (ED) with
bronchiolitis while adjusting for severity of illness. Our
secondary objectives were to determine the effect of
these bronchodilators in the subgroups of infants less
than 12 months of age and those presenting for the ﬁrst
time.
METHODS
Study Design
We conducted a two-site double-blind RCT comparing
nebulized racemic albuterol to nebulized racemic epi-
nephrine. Both sites had institutional review board
(IRB) approval for the study.
Study Setting and Population
The primary site was a county hospital ED with 53,000
attendances annually (23% children), serving a mixed
urban, rural, and suburban population. The secondary
site was a community teaching ED with an annual cen-
sus of 80,000 (20% children). Both hospitals have uni-
versity afﬁliations and emergency medicine residencies.
The secondary site also has a pediatric residency pro-
gram. Recruitment occurred from November 1, 2003, to
May 1, 2006, and from November 1, 2004, to May 1,
2006, at the primary and secondary sites, respectively.
We deﬁned bronchiolitis operationally as clinical evi-
dence of lower airway obstruction (physical ﬁndings of
wheezing and chest wall retractions) following an
upper respiratory tract infection
21 in children up to the
18th month of life. There was no lower age limit. The
adopted upper age cutoff represented a midpoint
between the ranges of accepted age limit (12 or
24 months) for deﬁning bronchiolitis.
4,18,21–23 We
excluded children with bronchiolitis who required no
treatment, those with illness so severe as to require
immediate intubation, and those who received bron-
chodilators in the ED prior to screening. In our attempt
to have broad inclusion criteria, we did not exclude
patients with a history of prior episodes of wheezing,
lung disease, or other comorbidity. Diagnosis was
made by an attending physician or midlevel provider.
All patients with a diagnosis of bronchiolitis judged
by the attending physician or physician assistant to
require treatment were eligible to be enrolled. The
treating physician screened and enrolled patients as
they presented to the ED. Signed informed consent was
obtained from a parent of all children enrolled.
Research assistants (RAs) assisted study investigators
at the primary site. All clinicians and RAs received reg-
ular training reinforcement in study procedures
throughout each bronchiolitis season. At the secondary
site, patients were screened and enrolled on a conve-
nience basis when a study attending physician or
research nurse was available.
Figure 1. Ordinal regression model. Reprinted, with permis-
sion, from Walsh P, Rothenberg SJ, O’Doherty S, Hoey H, Healy
R. A validated clinical model to predict the need for admission
and length of stay in children with acute bronchiolitis. Eur J
Emerg Med. 2004; 11(5):265–72.
19 HR = heart rate.
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Patients were randomized in blocks of 50 to receive
either three consecutive doses of nebulized racemic
albuterol or a single dose of nebulized racemic epineph-
rine followed by two nebulized saline treatments. The
large block size reduced the risk of allocation bias and
physicians being able to guess the identity of the drug.
Randomization was performed using a computer-gen-
erated random number series and was stratiﬁed per
site. The pharmacist had sole access to this list and the
codes were secured until the study was complete.
The dose of racemic albuterol given was 0.625 mg for
infants weighing less than 5 kg and 1.25 mg for those
weighing 5 kg or more. The dose of racemic epineph-
rine was 11.25 mg (0.5 mL of 2.25% solution) regardless
of weight. The hospital pharmacist prepared all of the
drug packets. Each were identical and presented in
sequentially numbered light-protective polythene pack-
ets containing three syringes with 0.5 mL of a clear
liquid, three 2.5-mL saline vials, a study label, and a
package insert with instructions to the user.
All patients received 2.5 mL of nebulized saline dur-
ing the consent process prior to randomization. Both
saline mist and study drugs were delivered using an
oxygen-driven VixOne small-volume nebulizer (West-
med, Inc., Tucson, AZ) at 20-minute intervals. A ﬂow
rate of 7 L⁄min was used with wall-mounted oxygen
switches and between 6 and 8 L⁄min with cylinder oxy-
gen. Patients received either three nebulized racemic
albuterol doses or one nebulized racemic epinephrine
dose, followed by two saline nebulizers.
Data were collected prospectively using standardized
forms to document history and physical exam. Data col-
lected included age, history of prematurity, medical his-
tory including previous episodes of wheezing, use of
albuterol or prednisone before arrival, and any family
history of asthma. A nurse recorded the vital signs,
including oxygen saturation, at triage, and a physician
recorded physical examination ﬁndings. When avail-
able, RAs scribed the data form and assisted with the
consent process.
Two hours following the administration of the ﬁrst
dose of the study drug, the treating physician could dis-
charge, admit, or give additional bronchodilators.
Patients in this last group were classiﬁed as having a
prolonged ED stay. Admission criteria are given in
Figure 2, although physicians could override these
criteria using clinical judgment.
24 Viral antigen testing,
steroid use, and discharge medications were ordered
according to the treating physician’s preference.
Outcome Measurements
The primary outcome was ‘‘successful discharge,’’
deﬁned as discharge following study drug administra-
tion, not requiring additional bronchodilators in the ED
and not resulting in admission within 72 hours of
discharge. Patients who were classiﬁed as having a pro-
longed ED stay were counted as admissions. Reatten-
dance within 72 hours (at a clinic, doctor’s ofﬁce, or
ED) that did not result in a hospital admission was con-
sidered a successful discharge. This outcome was cho-
sen to ensure that the discharge was appropriate and
not just temporarily deferred. We veriﬁed any further
medical contact by reviewing hospital records, tele-
phone follow-up, and checking county coroner’s
records to verify vital status where follow-up was
unsuccessful.
Severity of Illness
Severity-of-illness assignment
20 was performed elec-
tronically after data collection was complete but before
the randomization code was broken. The tool is com-
plex (Figure 1) and at present is designed for research
rather than clinical use.
Data Analysis
We calculated a sample size required to provide 90%
power (with two-sided alpha level of 0.05) based on
admission rates of 33% for patients treated with race-
mic epinephrine and 50% for racemic albuterol.
11 We
then rounded this simple sample estimate (n = 374) up
to 500 as recommended by Long,
25 anticipating logistic
regression as the method of analysis. An entire bron-
chiolitis season was used as the minimum unit of
recruitment to avoid potential bias from recruiting for
part of the season. There may be differences between
children who present early or late in the season.
Analyses were performed on an ‘‘intent-to-treat’’
basis. We analyzed only the ﬁrst enrollment of patients
who were enrolled more than once during the study.
We modeled severity as categorical variables rather
than as an ordinal variable. We created a fourth sever-
ity category, containing patients missing one or more
of the variables needed to determine illness severity.
Study site of enrollment was modeled as a categorical
variable. Owing to the relatively common outcome, we
estimated adjusted relative risks, (aRR), using modiﬁed
Poisson regression as described by Zou,
26 rather than
odds ratios. We present aRR with 95% conﬁdence
intervals (CIs) using successful discharge as the depen-
dent variable and study drug, severity of illness, and
study site as exposures. We also constructed other
models to account for the patients with missing obser-
vations on the severity scale by using multiple imputa-
tions and by excluding these cases from the model. We
also performed a Mantel-Haenszel simple stratiﬁed
analysis, stratifying only for disease severity.
Figure 2. Admission criteria.
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included in the primary analysis. It was felt that if a sig-
niﬁcant proportion of these patients improved sufﬁ-
ciently to be discharged posttreatment, this would be
an important ﬁnding. We excluded these in a sensitivity
analysis. We also excluded the prolonged ED treatment
group in a sensitivity analysis. We analyzed patients
with recurrent wheezing and patients over 12 months
of age both by excluding them and by constructing a
model with categorical variables for these and other
variables of potential interest. These sensitivity analyses
used a Poisson model with stepwise backward selection
to examine the effect of all the primary and secondary
endpoints by including the variables: patients with
recurrent wheezing, prematurity, age less than
2 months, steroid use, hypoxia, and a family history of
asthma.
We performed double data entry using a customized
Filemaker-Pro (Filemaker-Pro, Version 6, Santa Clara,
CA) database. Statistical analysis was performed using
Stata 9.2 (Release 10, Statacorp, College Station, TX).
RESULTS
A total of 721 patients were enrolled, 655 at one site
and 66 at the other. Following the exclusion of those
with eligibility violations or multiple enrollments, 703
were analyzed (Figure 3). The mean age of all patients
enrolled was 6 months (median 4.8 months), 407 (58%)
were male, and 610 (87%) were less than 12 months of
age. Respiratory syncytial virus antigen was present in
313 of the 553 (57%) patients tested in the ED. The
baseline characteristics are broadly similar and shown
in Table 1.
There were 352 patients in the racemic albuterol
group and 351 patients in the racemic epinephrine
group. Figure 4 shows the age distribution of patients
by treatment group. Patient ﬂow to their ultimate dis-
position is shown in Figure 5. Bronchiolitis was classi-
ﬁed as mild, moderate, and severe in 175, 419, and 47
children, respectively. The racemic albuterol group
had signiﬁcantly more (p = 0.007) moderately ill, but
fewer mildly ill, patients compared to the racemic epi-
nephrine group. Table 2 depicts the drug assignment
and disposition of each severity-of-illness category.
Patients were successfully discharged in 333 of 703
(47.4%) cases. Successful discharge decreased directly
with severity of illness: moderate (aRR = 0.49, 95%
CI = 0.42 to 0.57) and severe (aRR = 0.20, 95%
CI = 0.10 to 0.39), compared with mild disease. The
proportion of those successfully discharged in each
treatment arm for each severity-of-illness category is
shown in Figure 6.
Admission rates at the primary site were 52%
(331⁄640) and at the secondary site were 62% (39⁄63).
There were marginally signiﬁcantly fewer discharges in
the secondary site (aRR = 0.76, 95% CI = 0.56 to 1.03).
While discharge rates and outpatient treatment failures
were higher at the primary site, the use of clinical judg-
ment rather than other admission criteria, other patient
characteristics, and steroid use were similar at both
sites. Thirty-seven had a second ED visit within 3 days.
Six were readmitted within 3 days of initial ED dis-
charge in the racemic albuterol group and 10 patients
in the racemic epinephrine group, all from the primary
site. Forty-nine of 177 (27.7%) patients who met admis-
sion criteria at entry from the primary site were dis-
charged, while all of those who met admission criteria
at entry were admitted from the secondary site. Our
primary outcome results include adjustment for site.
Crude analysis (not adjusting for severity of illness)
showed no difference between groups (RR 1.08, 95%
CI = 0.92 to 1.26). After stratiﬁcation by severity of ill-
ness, patients who received racemic albuterol were sig-
niﬁcantly more likely than patients receiving racemic
epinephrine to be successfully discharged (aRR = 1.18,
95% CI = 1.02 to 1.36). This result was the same using
Poisson regression and Mantel-Haenszel stratiﬁed anal-
ysis. Excluding those in the ‘‘prolonged ED treatment’’
group did not change the treatment results (aRR = 1.16,
95% CI = 1.01 to 1.33) in Poisson regression. Racemic
albuterol’s advantage did not change in the sensitivity
analysis controlling for potential confounders age less
than 12 months, prematurity, hypoxia, and history of
prior wheezing (aRR 1.18, 95% CI = 1.02 to 1.37)
(Table 3).
A total of 187 patients met admission criteria at entry.
Some of these were successfully discharged (see
Table 2). Excluding those who met admission criteria
on entry had little effect on the results (aRR 1.22, 95%
CI = 1.04 to 1.43). Interrater reliability of the severity
assessment tool (assessed only at the primary site) was
substantial (j = 0.68).
27
Incomplete Data
The data required to calculate the severity of illness
were incomplete in 62 of 703 (8.8%) cases. Risk of Figure 3. Consort diagram.
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mild severity group (aRR = 0.89, 95% CI = 0.73 to 1.09).
Neither excluding these cases nor using multiple impu-
tations changed the results (analysis not shown).
Including only infants less than 12 months, using age
less than 12 months as a categorical variable or exclud-
ing subjects aged less than 2 months did not change
the signiﬁcant advantage of racemic albuterol over
racemic epinephrine. Patients with recurrent wheezing
were slightly less likely to be admitted (Table 3).
Adverse Effects
Tachycardia (deﬁned by heart rate above the 97th per-
centile for age) was noted before treatment in 88 of 352
(25%) in the racemic albuterol group and 74 of 351
(21%) in the racemic epinephrine group. Posttreatment
tachycardia was only noted in 52 (15%) in the former
and in 42 (12%) in the latter (p = 0.32). Two patients
Table 1
Baseline Patient Variables
Variable
Epinephrine
(n=351)
Albuterol
(n=352)
p-Value
(Univariate Testing)
Median age in months (IQR) 4.8 (6.2) 4.9 (6.1) 1.00
Male, N = 407 (57.9%) 213 (60.7) 194 (55.1) 0.15
Ex-premature (%) 61 (17.4) 69 (19.6) 0.50
Asthma or RAD in any member of immediate family 70 (19.9) 69 (19.6) 0.93
On albuterol before arrival in the ED, n (%) 60 (17.1) 64 (18.2) 0.77
On prednisone before arrival in the ED, n (%) 15 (4.3) 19 (5.4) 0.66
Temperature ‡ 38 C (%) 129 (36.8) 140 (39.8) 0.62
Age £ 2 months (%) 76 (21.7) 75 (21.3) 1.00
Age > 12 months (%) 52 (14.8) 41 (11.7) 0.22
First-time wheezing (%) 198⁄280 (70.7) 205⁄287 (71.4) 0.85
RSV antigen-positive (%) 152⁄276 (55.1) 161⁄277 (58.1) 0.49
SaO2 £ 92% (%) 35⁄344 (10.2) 25⁄342 (7.3) 0.22
SaO2 (±SD) 97 (4) 97 (3) 0.63
Mean temperature,  F (±SD) 100.0 (1.7) 99.9 (1.7) 0.55
Mean HR (±SD) 156 (24) 158 (23) 0.35
Mean RR (±SD) 47 (13) 46 (12) 0.50
Tachycardic (%) 74⁄350 (21.1) 88⁄352 (25.0) 0.25
Hydration status (%) n=342 n=346
Normal 303 (88.6) 303 (87.6)
5% dehydration 24 (7.0) 38 (11.0) 0.02
10% dehydration 14 (4.1) 5 (1.5)
15% dehydration 1 (0.3) 0 (0)
Increased work of breathing retraction severity (%) n=313 n=331
None 20 (6.4) 27 (8.2)
Mild 162 (51.8) 161 (48.6) 0.62
Moderate 115 (36.7) 130 (39.3)
Severe 16 (5.1) 13 (3.9)
ED = emergency department; HR = heart rate; IQR = interquartile range; RAD = reactive airway disease; RR = respiratory rate;
RSV = respiratory syncytial virus; SaO2 = oxygen saturation.
Figure 4. Age distribution of the study patients.
Figure 5. Numbers successfully discharged and admitted.
ED = emergency department.
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rapidly, and one received promethazine. Both were in
the racemic epinephrine group and had used cylinder
oxygen. One death in the racemic epinephrine group
was reported within 30 days.
DISCUSSION
Our crude results did not show a difference between
agents. When we adjusted for severity, we found a
lower risk of admission with the use of nebulized race-
mic albuterol when compared to racemic epinephrine
in children presenting to the ED with bronchiolitis. This
was an unexpected result and contrasted with
some,
11,15,28 although not all,
7–9,16 existing studies.
However, to the best of our knowledge, our study is
the largest to date examining this question. Our results
held true in all subgroups: hypoxia, age less than
12 months, prematurity, and a family history of asthma
do not alter the advantage of racemic albuterol over
racemic epinephrine in reducing admissions. Broad
inclusion criteria helped ensure adequate sample size.
Unlike many smaller studies, our sample represents the
breadth of bronchiolitis seen in the ED each season.
One of the ironies of bronchiolitis research is that
while bronchiolitis is agreed to be common, most stud-
ies of it are small. This is in part due to difﬁculties in
deﬁning the condition and distinguishing it from
asthma. The term asthma is itself so broad and ill-
deﬁned that at least one editorialist has called for the
term to be classiﬁed as a symptom rather than a diag-
nosis.
29 Furthermore, it is doubtful if asthma should
ever be diagnosed in the age group that we studied.
Our deﬁnition of bronchiolitis is consistent with the
often heterogeneous
28 deﬁnitions used by others.
21 We
have also addressed elements seen in other deﬁnitions
by both subgroup and multivariate analysis and consis-
tently obtained results favoring racemic albuterol.
Comparing pretreatment groups by the probability of
admission sets a substantially higher bar than simply
Table 2
Severity-of-illness and Outcomes Classiﬁcation for Each Treatment Group
Severity of Illness
(Total N=352)
Epinephrine with Data,
n=310 (Total N=351)
Albuterol with
Data, n=331
Successful discharge 160 (45.6) 173 (49.2)
Admitted 191 (54.2) 179 (50.9)
Met admission criteria at any time 181 (51.6) 186 (52.8)
Met admission criteria at any time
but successfully discharged
43⁄181 (23.8) 50⁄186 (26.9)
Met admission criteria on entry 96⁄321 (29.9) 91⁄337 (27.0)
Discharged despite meeting
admission criteria on entry
22⁄96 (22.9) 21⁄91 (23.1)
Discharged on albuterol 104⁄138 (75.4) 112⁄139 (80.6)
Mild 97⁄310 (31.0) 78⁄331 (23.6)
Successfully discharged 66⁄97 (68.0) 63⁄78 (80.8)
Moderate 193⁄310 (62.3) 228⁄331 (68.8)
Successfully discharged 63⁄192 (32.8) 93⁄227 (41.0)
Severe 21⁄310 (6.8) 26⁄331 (7.9)
Successfully discharged 2⁄21 (16.7) 5⁄26 (19.2)
Missing data 41⁄351 (11.7) 21⁄352 (6.0)
Successfully discharged 29⁄41 (70.7) 12⁄21 (57.1)
Figure 6. Summary of results. Successful discharge by severity
of illness. Alb = albuterol; Epi = epinephrine.
Table 3
Sensitivity Analyses to Assess the Importance of Other Variables
on Probability of Successful Discharge (the Beneﬁt of Albuterol
Was Unchanged by Their Inclusion)
Variable
aRR of
Successful
Discharge 95% CI p-Value
Albuterol 1.18 1.02, 1.37 0.026
Moderate* 0.51 0.44, 0.60 <0.001
Severe* 0.25 0.13, 0.49 <0.001
Not classiﬁed* 0.88 0.72, 1.08 0.216
Secondary site 0.84 0.63, 1.14 0.262
Age < 12 months 0.98 0.81, 1.18 0.805
Ex-premature 0.71 0.56, 0.89 0.003
Hypoxia 0.41 0.23, 0.74 0.003
Prior wheezing 1.36 1.14, 1.62 0.001
aRR = adjusted relative risk; CI = conﬁdence interval.
*Reference category is mild disease. n for this model is 686.
The same results for severity of illness and drug were
obtained using Mantel-Haenszel stratiﬁed analysis.
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between treatment arms. The latter method can lead to
the appearance of balance when in fact the preinterven-
tion probability of admission differs between groups.
The former requires a validated tool to predict admis-
sion and an adjusted analysis in the event that groups
are not balanced or much larger sample sizes to
increase the probability of treatment group balance or
subject pair matching at enrollment.
From a practical standpoint, implementation of sub-
ject–pair matching would require an automated system
deployed across several aggressively recruiting sites
that allows rapid input of patient data, classiﬁes severity
of disease, and ﬁnds a matching case. Such a solution is
clearly resource-intensive. We opted for simple enroll-
ment and subsequent adjustment for disease severity
using a validated tool, which was feasible and cost-
effective and minimized barriers to recruitment by
treating clinicians.
Had we ignored severity of illness, or assumed equal
pretreatment probability of discharge in each treatment
arm, we would have erroneously concluded that there
was no difference between the drugs. Our design
addressed the limitation that two relatively large groups
may have a similar distribution of potentially confound-
ing variables overall in each group, but have different
combinations of these confounders at the level of indi-
vidual subjects.
Failure to address this can result in erroneous inter-
pretation of RCTs, as has emerged when large trials
were reanalyzed.
30
We had anticipated this possibility in the design stage
and decided a priori to apply a severity-of-illness tool in
our analysis to adjust for the effect of severity of illness
on the probability of discharge within this sample.
Thereafter, we evaluated the additional effect of the
drugs on discharge risk. We consider this methodology
to be a design strength compared with previous
RCTs.
30
The choice of severity-of-illness tool is important. We
used the National Children’s Hospital (NCH) severity-
of-illness tool because it has been validated with
respect to need for admission. The relative complexity
of this tool precluded stratiﬁcation prior to enrollment.
The more widely used RDAI has been reported as hav-
ing almost perfect agreement (j = 0.9) for the wheezing
component and substantial agreement (j = 0.64) for the
presence of retractions component in its original
description. An overall kappa was not reported.
12 We
and others have found worse agreement for auscultato-
ry ﬁndings in infants,
21,31 but that overall the reliability
of our severity-of-illness tool (j = 0.68) was sufﬁcient to
permit its use. Previously employed severity-of-illness
or clinical scores have not been validated to predict dis-
position in bronchiolitis, whereas the model we used
has.
19
Our data show racemic albuterol leads to lower
discharge rates in each severity-of-illness stratum
(Figure 6), but that when these strata are combined
there is no difference. The Yule-Simpson ‘‘paradox’’
describes just this situation, where the success of
several subgroups may be reduced or even reversed
when these subgroups are combined.
32 The conditions
required for the ‘‘paradox,’’ namely, the combination of
an imbalance in the proportion of each subgroup
receiving each intervention and a different event rate in
each subgroup, are present in our data.
33 This combina-
tion requires inclusion of this confounding variable in a
multivariate regression analysis.
34 Almost identical
results were obtained using Mantel-Haenszel stratiﬁed
analyses.
Another difference between our study and others is
that determination of disposition was at 2 hours follow-
ing the initial nebulized treatment. This reﬂects the
widespread clinical practice of observing patients
following epinephrine, rather than immediately dis-
charging them. Our observation period ensured that
disposition was not prematurely decided based on
initial improvement. Studies have shown a beneﬁt in
clinical scores in the initial 15–60 minutes for infants
receiving epinephrine,
13,35 but overall this beneﬁt is
short-lived.
17 This study, however, does not exclude a
role for epinephrine. Further research is needed to
address which subsequent agent should be used follow-
ing inadequate response to albuterol or whether there
is a synergistic effect to using both.
LIMITATIONS
The age cutoff for inclusion in this study was a compro-
mise between the widely accepted deﬁnitions of less
than 1 or 2 years of age. Reducing the upper age limit
could reduce the enrollment of patients with recurrent
wheezing and perhaps some of those who may subse-
quently develop asthma. We reanalyzed the sample
population introducing age less than 12 months and
ﬁrst presentation as model variables. We also reana-
lyzed the sample after excluding patients over
12 months. In these alternative models, we continued to
ﬁnd results favoring racemic albuterol. Similarly, a his-
tory of recurrent wheezing or a family history of
asthma did not change the treatment effects. Conse-
quently, despite our broad inclusion criteria, our results
likely hold across even the subsets of children present-
ing to the ED with bronchiolitis, subsets represented by
some prior, more narrowly deﬁned, but inconclusive
studies.
The number of eligible patients not enrolled in the
study was unknown, as the primary site IRB did not
permit the collection of any information about patients
either who were not enrolled due to refusal of consent
or who had not been approached for consent. Anec-
dotal experience suggests that this number was small at
the primary site. We were not able to determine the
speciﬁc reason for admission, as we did not require
physicians to speciﬁcally document this.
The relatively low sample size in the secondary site
could be attributed to physician difference in diagnos-
ing bronchiolitis or the availability of researchers.
While it likely represents a convenience sample,
the results of the secondary site paralleled those at the
primary site. The numbers at the primary site, where
the recruitment period was longer, were a reﬂection of
the efforts of the investigators (who actively recruited
patients from the waiting room), availability of RAs up
to 16 hours a day, and widespread knowledge of the
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medical services. At the secondary site, a research
nurse was available 40 hours a week. We addressed
this difference in site recruitment by including site as a
variable in the model, where it approached statistical
signiﬁcance in its own right but did not alter albuterol’s
advantage.
Ideally, we would have performed stratiﬁed randomi-
zation, thereby avoiding the need for stratiﬁed or
adjusted analysis. However, the severity-of-illness tool
we used is complex and applying it at the randomiza-
tion stage would have posed a signiﬁcant barrier to
recruitment. It could also introduce bias if an investiga-
tor was enrolling the patient and knew the severity
score.
Potential Biases in Favor of Racemic Epinephrine
We accounted for missing data by creating a fourth
severity-of-illness category, by excluding these cases,
and by estimating their missing values using multiple
imputation.
35,36 In all cases, the treatment effects were
essentially the same regardless of statistical strategy.
Nonetheless, this is much less desirable than having
completed data sheets. This is particularly the case as
the number of incomplete data sheets was higher in
the racemic epinephrine than the racemic albuterol
group, potentially biasing the results. The nonsigniﬁ-
cant aRR of the incomplete data group means that it
cannot be distinguished from the mild group, poten-
tially indicating more mild-type cases in the epineph-
rine group. Neither dropping these cases nor multiple
imputations for these missing values changed our
results. Some patients could have received more or
less racemic albuterol than if we had dosed on a
strictly milligram per kilogram fashion, and some may
regard our doses as low. This could bias our results
against albuterol.
Potential Biases in Favor of Racemic Albuterol
The last dose of active medication in the albuterol
group was administered closer to the time that the dis-
position decision was made than in the racemic epi-
nephrine group. This would bias the results against
epinephrine assuming that racemic albuterol has an
advantage over saline.
Using a single dose of racemic epinephrine, rather
than three doses, reﬂects clinical practice. The dose of
racemic epinephrine (11.25 mg regardless of weight;
others have used 0.15 to 0.9 mg⁄kg)
15,28 is comparable
to that used for treating croup. This relatively high dos-
age minimized the potential disadvantage of using a
single dose.
Potential Biases to the Null
All patients received saline mist during the consent
process prior to randomization. If saline mist has a
beneﬁt, this would bias the study to the null. We used
saline nebulizers following the racemic epinephrine
treatment to maintain blinding. Again, any beneﬁcial
effect of saline would have biased the study to the
null.
Racemic albuterol was prescribed equally among
those discharged from each treatment arm. This
would be expected to narrow the differences in
unscheduled admissions between treatment groups
following discharge and increase the likelihood of a
Type 2 error.
We would have liked to control for discharge medi-
cations, but to achieve this would have required
unanimous agreement from all the EPs, pediatricians,
and family physicians serving the study site and
would likely have prevented the study from proceed-
ing. We found discharge medications to be similar
between groups.
CONCLUSIONS
In children up to the 18th month of life presenting to
the ED with a clinical diagnosis of bronchiolitis, race-
mic albuterol, rather than racemic epinephrine, should
be the initial agent chosen, as doing so modestly
increases the rate of successful discharge.
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